Tesamorelin & Ipamorelin Blend
A research blend combining tesamorelin (a stabilized GHRH analogue) with ipamorelin for synergistic GH release, combining tesamorelin's unique visceral fat research profile with ipamorelin's clean GHS selectivity.
Community Rating
No ratings yet
Compound Profile
Tesamorelin & Ipamorelin Blend
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Tesamorelin & Ipamorelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Synergistic GH release via GHRHR + GHS-R1a
- Tesamorelin's documented human visceral fat reduction effect
- Ipamorelin's clean GH selectivity (minimal cortisol/prolactin)
- Tesamorelin & Ipamorelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Synergistic GH release via GHRHR + GHS-R1a
- Tesamorelin's documented human visceral fat reduction effect
- Ipamorelin's clean GH selectivity (minimal cortisol/prolactin)
- Well-characterized human clinical data from tesamorelin component
In Plain English
Simple summaryThink of Tesamorelin & Ipamorelin Blend as a signalling molecule your body already recognises, it doesn't introduce anything foreign, it tells specific cells to do things they're already capable of doing, just more efficiently.
- Synergistic GH release via GHRHR + GHS-R1a
- Tesamorelin's documented human visceral fat reduction effect
- Ipamorelin's clean GH selectivity
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Tesamorelin & Ipamorelin Blend?
Tap any underlined term for an instant definition.
Tesamorelin & Ipamorelin Blend pairs tesamorelin, a stabilized trans-3-hexenoic acid-modified GHRH analogue (FDA approved as Egrifta for HIV lipodystrophy), with ipamorelin. The combination leverages tesamorelin's more stable GHRH-pathway activation and its documented clinical-level visceral fat reduction effect, amplified by ipamorelin's clean GHS-R1a-mediated somatostatin suppression.
What It Is
- Tesamorelin: a modified GHRH analogue with a trans-3-hexenoic acid substitution at position 1, improving resistance to dipeptidyl peptidase IV degradation; FDA approved for HIV-associated lipodystrophy
- Ipamorelin: selective GHS-R1a agonist with minimal off-target hormone effects
- Combination designed to capture tesamorelin's documented clinical fat-reduction profile with amplified GH release from ipamorelin co-administration
How It Works
- Tesamorelin activates GHRHR with slightly longer duration of action than sermorelin due to its stability modification
- Ipamorelin suppresses hypothalamic somatostatin and independently stimulates GHS-R1a
- Synergistic GH pulses exceed tesamorelin alone by 2-3 fold in animal models
Key Research Findings
- Tesamorelin alone (from clinical trials): 26 week treatment reduced visceral adipose tissue by 15-18% in HIV lipodystrophy patients vs placebo; IGF-1 increased 100-150%
- Combination: Limited direct combination trial data; extrapolation from component data suggests enhanced GH and IGF-1 vs either alone
- Visceral fat: Tesamorelin's documented anti-adiposity effect through GH-mediated lipolysis
Dosing From the Literature
- Tesamorelin: 1-2 mg subcutaneous daily (FDA approved dose: 2 mg/day)
- Ipamorelin: 200-300 mcg subcutaneous, co-administered
- Once daily administration preferred
Storage and Handling
- Lyophilised tesamorelin: 2-8 degrees C; 24 months
- Reconstituted: 2-8 degrees C; use within 21 days
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Tesamorelin & Ipamorelin Blend. See all Peptide Blends peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Subcutaneous injection. Tesamorelin should be administered once daily for sustained clinical-level GH stimulation.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Tesamorelin & Ipamorelin Blend, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Tesamorelin & Ipamorelin Blend has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: synergistic gh release via ghrhr + ghs-r1a.
The most commonly reported side effect in research subjects is injection site reactions. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
More in Peptide Blends
- Sermorelin & Ipamorelin Blend
- Sermorelin & GHRP-2 Blend
- Sermorelin & GHRP-6 Blend
- Sermorelin & GHRP-6 & GHRP-2 Triple Blend
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.